Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Phase 3pelacarsenNeutral

AI Analysis

Summary

Novartis announces topline results from the Lp(a)HORIZON Phase III trial of pelacarsen in patients with elevated Lp(a) and established cardiovascular disease. The article does not specify trial outcome details or efficacy results.

Clinical Trial Data

Phase

Phase III

Importance:8/10

Sentiment:

0.00

Phase 3topline resultscardiovascular diseaseLp(a)pelacarsen

Related Companies

$NVS

Read the original article

Published by GlobeNewswire Pharma on September 4, 2026 8:30 PM

Read Original